Sleep disorders/insomnia symptoms Sleep Disorders Thai massage (NuadThai) Transcranial Magnetic Stimulation Melatonin
Conditions
Interventions
Thai massage,Low frequency rTMS at 1 Hz delivered at 90 percentage of the individual RMT is known to produce an inhibitory effect on cortical excitability. The stimulation target was localized at the
Experimental Other,Experimental Other,Experimental Drug
Thai massage ,Transcraneal magnatic stimulation (TMS),Melatonin
Sponsors
National Research council of Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 and 60 years. 2. Participants with a Pittsburgh Sleep Quality Index (PSQI) score of 6 or higher. 3. who have been clinically diagnosed by a physician with insomnia that interferes with daily functioning.
Exclusion criteria
Exclusion criteria: 1. Individuals with psychiatric disorders. 2. Individuals with neurological disorders. 3. Individuals who are pregnant or breastfeeding. 4. Individuals with hepatic and/or renal diseases. 5. Individuals with cardiovascular and/or heart diseases. 6. Individuals with implanted electronic devices, such as: 6.1 Programmable VP/LP shunts, 6.2 Cochlear implants, 6.3 Cortical or deep brain stimulators, 6.4 Spinal cord stimulators, or 6.5 Cardiac pacemakers. 7. Individuals with metallic implants in the body, such as: 7.1 Vascular stents, 7.2 Aneurysm clips, 7.3 Orthopedic fixation devices or joint prostheses, 7.4 Retained bullets, 7.5 Tattoos containing metallic pigments, or 7.6 Metallic threads used in cosmetic procedures. 8. Individuals at risk of seizures, including those with: 8.1 Epilepsy or uncontrolled seizure disorders, 8.2 Recent adjustment of antiepileptic medication within the past six months, 8.3 Large cortical lesions, 8.4 Chronic alcohol or substance abuse, or 8.5 Severe sleep deprivation. 9. Individuals with venous thrombosis, infected wounds, unhealed fractures, or cancer in the area to be stimulated by magnetic fields. 10. Individuals with known hypersensitivity to any components of melatonin, including: Ammonio methacrylate copolymer type B, calcium hydrogen phosphate dihydrate, lactose monohydrate, colloidal anhydrous silica, talc, and magnesium stearate. 11. Individuals who are currently receiving other treatments for sleep disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pittsburgh Sleep Quality Index : PSQI at baseline and post-intervention 0-21; patient-reported questionnaire.,Insomnia Severity Index : ISI at baseline, during intervention 2 weeks and post-intervention 0-28; patient-reported questionnaire.,Electroencephalogram : EEG During the scheduled EEG recording session Standard EEG recording during sleep | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep Diary Daily throughout the duration of the study Daily self-reported sleep diary,36-Item Short Form Health Survey (SF-36) At baseline and post-intervention. 0-100 ; patient-reported questionnaire.,Pain Pressure Threshold At baseline and post-intervention. Measured using a pressure algometer. | — |
Countries
Thailand
Contacts
Public ContactNongnuch Luangpon
Faculty of Allied Health Sciences, Burapha University
Outcome results
None listed